Drug Profile
Monalizumab - Innate Pharma
Alternative Names: Anti-NKG2A; IPH-22; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer AstraZeneca; Innate Pharma; Istituto Clinico Humanitas; NCIC Clinical Trials Group; Netherlands Cancer Institute; Novo Nordisk
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily C antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Acute myeloid leukaemia; HER2 positive breast cancer; Myelodysplastic syndromes; Small cell lung cancer; Squamous cell cancer
- Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- No development reported Haematological malignancies
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 30 Nov 2023 Assistance Publique plans a phase II trial for Cancer (Combination therapy, Metastatic disease, Late-stage disease,Second-line therapy or greater) in France (NCT06152523)
- 20 Oct 2023 Efficacy and adverse events data from the phase II UPSTREAM trial in squamous cell cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 - Safety and efficacy data from the phase III INTERLINK-1 trial in Squamous cell carcinoma (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)